The therapeutic value of SC66 in human renal cell carcinoma cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The PI3K-AKT-mTOR pathway is crucial for renal cell carcinoma (RCC) progression.
• SC66 is a novel inhibitor targeting the AKT pathway.

Purpose of the Study:

• To investigate the efficacy and mechanisms of SC66 in inhibiting RCC cell viability, proliferation, migration, and invasion.
• To explore the AKT-dependent and independent pathways through which SC66 exerts its cytotoxic effects in RCC.

Main Methods:

• In vitro studies using RCC cell lines (786-O, A498) and patient-derived primary cells to assess viability, proliferation, migration, and invasion.
• Analysis of AKT-mTOR pathway activation, reactive oxygen species (ROS) production, sphingosine kinase 1 (SphK1) activity, ceramide levels, and JNK activation.
• In vivo studies using subcutaneous 786-O xenograft mouse models to evaluate SC66's anti-tumor efficacy.

Main Results:

• SC66 significantly inhibited viability, proliferation, migration, and invasion in various RCC models.
• SC66 demonstrated cytotoxicity even in AKT-inhibited or silenced RCC cells, suggesting AKT-independent mechanisms.
• SC66-induced cytotoxicity involves ROS production, SphK1 inhibition, ceramide accumulation, and JNK activation.
• Oral administration of SC66 potently inhibited tumor growth in a 786-O xenograft mouse model.
• Tumor analysis revealed AKT-mTOR inhibition, SphK1 inhibition, ceramide accumulation, and JNK activation in SC66-treated xenografts.

Conclusions:

• SC66 is a potent inhibitor of RCC progression through both AKT-dependent and AKT-independent pathways.
• SC66's anti-cancer effects are mediated by ROS production, SphK1 inhibition, ceramide accumulation, and JNK activation.
• SC66 represents a promising therapeutic agent for renal cell carcinoma.